July 06, 2026 04:22 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
China tests ballistic missile from nuclear submarine in Pacific: Australia, New Zealand respond | Baruipur horror: Main accused in alleged rape and murder of minor girl arrested; senior cops dissatisfied with handling of the case | Defence stocks jump after Rs 52,000 crore DAC approval sparks buying frenzy | 'Harry Kane is a great player': Donald Trump after England knocked Mexico out of the World Cup | 'Referee gave a lot against us': Harry Kane reacts after England's dramatic win over Mexico | England hold nerve with 10 men to knock out Mexico in five-goal World Cup classic | 'Why can't citizens protest against the government? They are being made slaves by slapping cases': Bombay HC slams Mumbai Police, quashes activist's externment | 'First he cheats on me...': Siya Goyal's old pub video goes viral amid probe into fiancé Ketan Agarwal's alleged murder | Ronaldo's goal, Ramos' last-gasp winner send Portugal past Croatia, set up Spain clash | India-US trade deal almost done! Piyush Goyal hints at breakthrough
Covid-19 vaccines

Two Covid-19 vaccine candidates await DCGI approval for emergency use in India

| @indiablooms | Jan 03, 2021, at 04:24 pm

New Delhi/IBNS: Two Covid-19 vaccine candidates in India-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-now awaits the approval of the Drugs Controller General of India (DCGI) for emergency use after they have been cleared by the government-appointed panel.

DCGI chief Dr Venugopal G Somani is expected to share details about the vaccine candidates on Sunday.

The government-appointed panel of experts on Saturday cleared the emergency use of indigenous COVID-19 vaccine Covaxin manufactured by Hyderabad-based Bharat Biotech and recommended for approval to the regulator Drugs Controller General of India (DCGI).

The recommendation for the home-grown vaccine came a day after the expert panel cleared Covishield developed by Oxford University and pharma major AstraZeneca to be manufactured by Serum Institute of India (SII).

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) recommended the Drugs Controller General of India (DCGI) to grant permission to Bharat Biotech's Covaxin.

According to reports, the SEC met on Jan 1 and 2 and made the recommendations for the consideration and final decision of DGCI, said the Union Health Ministry.

The Serum Institute of India (SII) is making the vaccine Covishield developed by Oxford University and pharma major AstraZeneca, while Bharat Biotech has partnered with the Indian Council of Medical Research (ICMR) for its indigenous Covaxin.

The final decision to recommend Bharat Biotech's Covaxin came after it presented updated data and justification and request for consideration of their proposal amid cases of mutant Coronavirus strain.

The committee noted that the vaccine has the potential to target mutated coronavirus strains, media reports said.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.